Development of selective inhibitors and substrate of matrix metalloproteinase-12

被引:133
作者
Devel, L
Rogakos, V
David, A
Makaritis, A
Beau, F
Cuniasse, P
Yiotakis, A
Dive, V
机构
[1] Ctr Etud Saclay, Dept Ingn & Etud Prot, Commissariat Energie Atom, F-91191 Gif Sur Yvette, France
[2] Univ Athens, Dept Organ Chem, Organ Chem Lab, GR-15771 Athens, Greece
关键词
D O I
10.1074/jbc.M600222200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Four phosphinic peptide libraries with compounds having the general formula p-Br-Ph-(PO2-CH2)-Xaa'-Yaa'-Zaa'-NH2 have been prepared and screened against 10 matrix metalloproteinases ( MMPs). We identified two phosphinic peptides with K-i values of 0.19 and 4.4 nM toward MMP-12 ( macrophage elastase) that are more than 2 - 3 orders of magnitude less potent toward the other MMPs tested. These highly selective MMP-12 inhibitors contain a Glu-Glu motif in their Yaa'-Zaa' positions. Incorporation of this Glu-Glu motif into the sequence of a nonspecific fluorogenic peptide cleaved by MMPs provides a highly selective substrate for MMP-12. A model of one of these inhibitors interacting with MMP-12 suggests that the selectivity observed might be due, in part, to the presence of two unique polar residues in MMP-12, Thr(239) and Lys(177). These MMP-12-selective inhibitors may have important therapeutic applications to diseases in which MMP-12 has been suggested to play a key role, such as in emphysema, atherosclerosis, and aortic abdominal aneurysm.
引用
收藏
页码:11152 / 11160
页数:9
相关论文
共 55 条
[1]   Conformational variability of matrix metalloproteinases: Beyond a single 3D structure [J].
Bertini, I ;
Calderone, V ;
Cosenza, M ;
Fragai, M ;
Lee, YM ;
Luchinat, C ;
Mangani, S ;
Terni, B ;
Turano, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (15) :5334-5339
[2]  
Bode W, 2003, BIOCHEM SOC SYMP, V70, P1
[3]   Timeline - Matrix metalloproteinases: a tail of a frog that became a prince [J].
Brinckerhoff, CE ;
Matrisian, LM .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (03) :207-214
[4]   CHARMM - A PROGRAM FOR MACROMOLECULAR ENERGY, MINIMIZATION, AND DYNAMICS CALCULATIONS [J].
BROOKS, BR ;
BRUCCOLERI, RE ;
OLAFSON, BD ;
STATES, DJ ;
SWAMINATHAN, S ;
KARPLUS, M .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 1983, 4 (02) :187-217
[5]   Quest for selectivity in inhibition of matrix metalloproteinases [J].
Brown, S ;
Meroueh, SO ;
Fridman, R ;
Mobashery, S .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (12) :1227-1238
[6]   Matrix metalloproteinases: Role in arthritis [J].
Burrage, PS ;
Mix, KS ;
Brinckerhoff, CE .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2006, 11 :529-543
[7]   The canonical methionine 392 of matrix metalloproteinase 2 (gelatinase A) is not required for catalytic efficiency or structural integrity - Probing the role of the methionine-turn in the metzincin metalloprotease superfamily [J].
Butler, GS ;
Tam, EM ;
Overall, CM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (15) :15615-15620
[8]   Synthesis and evaluation of novel oxazoline MMP inhibitors [J].
Cook, GR ;
Manivannan, E ;
Underdahl, T ;
Lukacova, V ;
Zhang, YF ;
Balaz, S .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (19) :4935-4939
[9]  
Cornelius LA, 1998, J IMMUNOL, V161, P6845
[10]   Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations [J].
Coussens, LM ;
Fingleton, B ;
Matrisian, LM .
SCIENCE, 2002, 295 (5564) :2387-2392